These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16296776)

  • 41. Electrostatics of pharmaceutical inhalation aerosols.
    Kwok PC; Chan HK
    J Pharm Pharmacol; 2009 Dec; 61(12):1587-99. PubMed ID: 19958580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolution of dry powder inhaler design, formulation, and performance.
    Newman SP; Busse WW
    Respir Med; 2002 May; 96(5):293-304. PubMed ID: 12113378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of computational fluid dynamics in inhaler design.
    Ruzycki CA; Javaheri E; Finlay WH
    Expert Opin Drug Deliv; 2013 Mar; 10(3):307-23. PubMed ID: 23289401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review of the TAIFUN multidose dry powder inhaler technology.
    Overhoff KA; Clayborough R; Crowley M
    Drug Dev Ind Pharm; 2008 Sep; 34(9):960-5. PubMed ID: 18686086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advancements in dry powder delivery to the lung.
    Son YJ; McConville JT
    Drug Dev Ind Pharm; 2008 Sep; 34(9):948-59. PubMed ID: 18800256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-use disposable dry powder inhalers for pulmonary drug delivery.
    Friebel C; Steckel H
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1359-72. PubMed ID: 21080859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a high-throughput UHPLC-MS-based content uniformity method as a tool for assessing dry powder inhalers.
    Medendorp J; Donovan B; Pennington J
    Drug Dev Ind Pharm; 2010 Jul; 36(7):762-72. PubMed ID: 20136489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of disposable inhalers in pulmonary drug delivery.
    de Boer AH; Hagedoorn P
    Expert Opin Drug Deliv; 2015 Jan; 12(1):143-57. PubMed ID: 25374325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer(®).
    Jiang L; Tang Y; Zhang H; Lu X; Chen X; Zhu J
    J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):265-79. PubMed ID: 22280548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New propellant-free technologies under investigation.
    Dolovich M
    J Aerosol Med; 1999; 12 Suppl 1():S9-17. PubMed ID: 10623341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methacholine dry powder inhaler as a new tool for bronchial challenge test.
    Colombo G; Terzano C; Colombo P; Petroianni A; Ricci A; Buttini F
    Int J Pharm; 2008 Mar; 352(1-2):165-71. PubMed ID: 18055141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI).
    Hoe S; Traini D; Chan HK; Young PM
    Eur J Pharm Sci; 2009 Sep; 38(2):88-94. PubMed ID: 19559086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):72-80. PubMed ID: 16442248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
    Westerman EM; Heijerman HG; Frijlink HW
    Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In-line assessment of pulmonary drug delivery using light obscuration.
    Kusmartseva O; Kattige AS; Price R; Smith PR
    Biosens Bioelectron; 2004 Oct; 20(3):468-74. PubMed ID: 15494227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Importance of inhaler devices in the management of airway disease.
    Virchow JC; Crompton GK; Dal Negro R; Pedersen S; Magnan A; Seidenberg J; Barnes PJ
    Respir Med; 2008 Jan; 102(1):10-9. PubMed ID: 17923402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers.
    Buttini F; Rozou S; Rossi A; Zoumpliou V; Rekkas DM
    Eur J Pharm Sci; 2018 Feb; 113():64-76. PubMed ID: 29104067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation.
    Sebti T; Amighi K
    Eur J Pharm Biopharm; 2006 May; 63(1):51-8. PubMed ID: 16380243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.